A Randomized, Open Label, Single-Centre, Single-Dose, 4-Period, 4-Treatment Cross-over Study to Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution (SDK001) Under Fasting and Fed Conditions, to Compare to Intravenous Arsenic Trioxide, and to Evaluate Interaction with Calcium Carbonate in Patients with Acute Promyelocytic Leukemia.
Randomized, Open-Label Study to evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution (SDK001) under Fasting and Fed Conditions, to Compare to IV Arsenic Trioxide
100 项与 SDK Therapeutics, Inc 相关的临床结果
0 项与 SDK Therapeutics, Inc 相关的专利（医药）
100 项与 SDK Therapeutics, Inc 相关的药物交易
100 项与 SDK Therapeutics, Inc 相关的转化医学
